<p>CRISPR Therapeutics（纳斯达克代码：CRSP）在过去一周内显著上涨了 25%，在高管离职的背景下获得了关注。首席运营官 Julianne Bruno 的离职公告可能影响了投资者情绪，反映出公司内部的战略调整。这一价格波动在整体市场上涨的背景下显得尤为突出，因为主要指数因美中贸易紧张关系面临下行压力，尤其是科技行业。然而，整体市场在过去七天上涨了 8%，这表明 CRISPR 的价格波动可能与这些更广泛的趋势相一致或受到放大。</p>
<p>我们发现 CRISPR Therapeutics 有一个需要注意的弱点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth"/></p>
<p>截至 2025 年 4 月的纳斯达克代码：CRSP 每股收益增长</p>
<p>我们发现 25 只美国股票预计明年将支付超过 6% 的股息收益率。请查看完整列表，免费获取。</p>
<p>CRISPR Therapeutics 的股票在过去五年中经历了-23.48% 的总回报，突显出公司面临的挑战。相比之下，仅在过去一年，CRISPR 的表现显著低于美国市场，后者上涨了 5.9%，以及美国生物技术行业，后者下降了 7.2%。</p>
<p>在首席运营官离职公告后，CRISPR 股价的快速上涨可能会影响收入和盈利预测，可能表明战略重组。考虑到公司当前的收入预测显示每年有 53.64% 的显著增长，管理层变动可能会影响投资者信心和公司发展轨迹。尽管有上行势头，股价仍远低于分析师共识目标价 82.83 美元，表明市场未来可能会重新评估。</p>
<p>根据我们最近的估值报告，CRISPR Therapeutics 似乎交易在其估计价值之下。</p>
<p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>如果您想交易 CRISPR Therapeutics，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
<p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
<p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
<p>赞助内容</p>

CRISPR治疗

<p>CRISPR Therapeutics（纳斯达克代码：CRSP）在过去一周内股价上涨了 25%，这受到首席运营官 Julianne Bruno 离职的影响。这一上涨与更广泛的市场趋势形成对比，主要指数因美中贸易紧张局势而承压。尽管最近有所上涨，CRISPR 在过去五年的总回报为-23.48%，并且表现不及美国市场和生物技术行业。当前股价仍低于分析师共识目标价 82.83 美元，显示出未来重新评估的潜力</p>

<p>CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced investor sentiment, potentially reflecting strategic shifts within the company. This price movement stands out against a backdrop of broader market gains, as major indexes faced downward pressure due to trade tensions between the U.S. and China, particularly affecting the technology sector. However, the market overall rose by 8% in the last seven days, suggesting that CRISPR's movements might align with or have been amplified by these broader trends.</p>
<div class="lb-trans"><p>CRISPR Therapeutics（纳斯达克代码：CRSP）在过去一周内显著上涨了 25%，在高管离职的背景下获得了关注。首席运营官 Julianne Bruno 的离职公告可能影响了投资者情绪，反映出公司内部的战略调整。这一价格波动在整体市场上涨的背景下显得尤为突出，因为主要指数因美中贸易紧张关系面临下行压力，尤其是科技行业。然而，整体市场在过去七天上涨了 8%，这表明 CRISPR 的价格波动可能与这些更广泛的趋势相一致或受到放大。</p>
</div><p>We've identified 1 weakness for CRISPR Therapeutics that you should be aware of.</p>
<div class="lb-trans"><p>我们发现 CRISPR Therapeutics 有一个需要注意的弱点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth" alt="" original-src="https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth"/></p>
<p>NasdaqGM:CRSP Earnings Per Share Growth as at Apr 2025</p>
<div class="lb-trans"><p>截至 2025 年 4 月的纳斯达克代码：CRSP 每股收益增长</p>
</div><p>We've found 25 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我们发现 25 只美国股票预计明年将支付超过 6% 的股息收益率。请查看完整列表，免费获取。</p>
</div><p>CRISPR Therapeutics' shares have experienced a substantial -23.48% total return over the past five years, highlighting a challenging period for the company. In contrast, over the last year alone, CRISPR significantly underperformed compared to both the US market, which saw a 5.9% increase, and the US Biotechs industry, which experienced a decline of 7.2%.</p>
<div class="lb-trans"><p>CRISPR Therapeutics 的股票在过去五年中经历了-23.48% 的总回报，突显出公司面临的挑战。相比之下，仅在过去一年，CRISPR 的表现显著低于美国市场，后者上涨了 5.9%，以及美国生物技术行业，后者下降了 7.2%。</p>
</div><p>The recent quick uptick in CRISPR's share price, following the COO's departure announcement, could affect revenue and earnings projections by potentially indicating strategic realignment. Given that the company's current revenue forecast suggests substantial growth at 53.64% per year, changes in executive roles might influence investor confidence and corporate trajectory. Despite the upward momentum, the share price remains well below the analyst consensus price target of US$82.83, suggesting room for future reassessment by the market.</p>
<div class="lb-trans"><p>在首席运营官离职公告后，CRISPR 股价的快速上涨可能会影响收入和盈利预测，可能表明战略重组。考虑到公司当前的收入预测显示每年有 53.64% 的显著增长，管理层变动可能会影响投资者信心和公司发展轨迹。尽管有上行势头，股价仍远低于分析师共识目标价 82.83 美元，表明市场未来可能会重新评估。</p>
</div><p>In light of our recent valuation report, it seems possible that CRISPR Therapeutics is trading behind its estimated value.</p>
<div class="lb-trans"><p>根据我们最近的估值报告，CRISPR Therapeutics 似乎交易在其估计价值之下。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>If you're looking to trade CRISPR Therapeutics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.</p>
<div class="lb-trans"><p>如果您想交易 CRISPR Therapeutics，请在专业人士信赖的最低成本平台 Interactive Brokers 开设账户。</p>
</div><p>With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.</p>
<div class="lb-trans"><p>IBKR 在 200 多个国家和地区拥有客户，并可访问 160 个市场，让您可以通过一个集成账户交易股票、期权、期货、外汇、债券和基金。</p>
</div><p>Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.</p>
<div class="lb-trans"><p>享受无隐藏费用，无账户最低要求，外汇转换率低至 0.03%，远低于大多数经纪商提供的费用。</p>
</div><p>Sponsored Content</p>
<div class="lb-trans"><p>赞助内容</p>
</div>

CRISPR Therapeutics（纳斯达克股票代码：CRSP）在过去一周内价格上涨了 25%